Alliance Pharma updates on Diclectin

05:37 EDT 31 Jul 2017 | Proactive Investors

Alliance Pharma plc (LON:APH) on Friday told investors that the UK healthcare regulator has not approved a marketing authorisation submission for Diclectin. The product is a treatment for nausea and vomiting of pregnancy. It was in-licenced from Duchesnay Inc for the UK in 2015 and for a further nine European territories in 2016, and £1.5mln was paid to Duchesnay for all territories. “Whilst this is disappointing news, this will have no material impact on the company's expected near-term results,” the company said in a note. The company’s comments were echoed by finnCap analyst Mark Brewer who, in a note, said: “The announcement late on Friday that the UK’s regulator (MHRA) has not approved Diclectin for the treatment of nausea and vomiting of pregnancy (NVP) is clearly a disappointment, although not detrimental to near-term forecasts given the stronger than expected interim trading update.”

Original Article: Alliance Pharma updates on Diclectin


More From BioPortfolio on "Alliance Pharma updates on Diclectin"

Quick Search

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...